A new genetic clue in Alzheimer’s may be hiding in the brain’s immune cells
Researchers at Boston Children’s Hospital and collaborators report that microglia, the brain’s resident immune cells, can accumulate mutations in cancer-driving genes without turning cancerous. Instead, the team found evidence that these altered cells may help create the inflammatory conditions associated with Alzheimer’s disease.
The work, published in Cell, adds an unexpected layer to the Alzheimer’s puzzle. Rather than focusing only on hallmark protein buildups such as amyloid and tau, the study points toward a cellular selection process in which certain mutated immune cells may gain a survival advantage in the diseased brain. The result, according to the researchers, could be a more hostile environment for neurons.
What the team examined
The researchers sequenced 149 cancer-driving genes in tissue from 190 donated brains from people with Alzheimer’s disease and compared those findings with 121 healthy brains. The Alzheimer’s samples contained more single-letter DNA changes than the healthy tissue. More importantly, the mutations were not randomly scattered: the same five cancer driver genes appeared repeatedly.
That pattern suggests the changes are not simply background wear and tear from aging. Instead, the mutated microglia may be undergoing a kind of selection process. In an environment shaped by Alzheimer’s pathology, those cells may survive and proliferate better than neighboring cells, potentially reinforcing inflammation over time.
Why microglia matter
Microglia act as the brain’s front-line immune system. They help clear debris, respond to injury, and monitor the local environment. In Alzheimer’s disease, those cells are already known to play a major role in how the brain responds to accumulating toxic proteins. The new study suggests that some microglia may also be genetically altered in ways that change how they behave.
The researchers describe an interaction between two processes. On one side, abnormal protein clumps such as amyloid and tau make the brain’s environment increasingly damaging. On the other, microglia carrying mutations in cancer-linked genes may be more likely to persist and expand under those conditions. The consequence could be chronic inflammatory activity that harms otherwise healthy neurons nearby.
The comparison to cancer is provocative, but the authors are not arguing that Alzheimer’s is literally a brain cancer. Their point is narrower and more useful: some of the same types of mutations that help blood cancers emerge may also shape non-cancer disease biology in the brain.
Why the finding stands out
Much Alzheimer’s research has concentrated on misfolded proteins, synaptic loss, vascular factors, and inherited risk variants. This study introduces somatic mutation in immune cells as another possible contributor. Somatic mutations are genetic changes acquired over life rather than inherited at birth, and the authors note that cells naturally build up many such mutations with age.
What makes this result notable is that the mutations appeared enriched in genes already known from oncology. That raises the possibility that aging brains are not only accumulating damage but also selecting cell populations that behave differently under stress.
It also offers a possible explanation for why Alzheimer’s can progress in ways that look self-reinforcing. If disease conditions favor the expansion of microglia carrying particular mutations, inflammation may become harder to shut down once it is established.
Therapeutic implications, with caution
Lead investigator Christopher Walsh said the overlap with cancer biology may be useful because medicine already has an extensive toolkit for targeting cancer pathways. That does not mean oncology drugs are ready to be repurposed directly for Alzheimer’s patients. But it does create a more concrete starting point for exploring diagnostics and treatments that act on these altered microglial populations.
The most immediate value may be conceptual. Alzheimer’s has long resisted simple explanations and simple interventions. A model that includes mutation-bearing immune cells could help explain why anti-inflammatory strategies have often produced mixed results: the disease may involve not only inflammation, but a changing population of cells that sustains it.
Future work will need to show how early these mutations arise, whether they can be detected reliably in living patients, and whether reducing the influence of those cell populations changes clinical outcomes. The current study is a strong signal, but not yet proof that the mutations are a central driver in every case.
A broader shift in how Alzheimer’s is framed
The study reflects a larger trend in medicine: diseases once treated as single-process disorders are increasingly being understood as ecosystems. In Alzheimer’s, neurons, immune cells, protein deposits, and now acquired mutations may all interact. That is more complicated than a one-cause narrative, but it also opens more paths for intervention.
If the findings hold up in follow-on studies, they could push Alzheimer’s research toward questions that have so far been more common in cancer biology: clonal selection, cellular competition, and the role of acquired mutations in disease progression. For a field in need of fresh angles, that is a meaningful development.
The central message is not that Alzheimer’s and cancer are the same disease. It is that the aging brain may be shaped by some of the same genetic dynamics that medicine already knows how to study in tumors and blood disorders. That insight could eventually matter for both earlier detection and more targeted treatment.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
